US23282W6057
© Globe Newswire
12.12.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
News Preview
Final Decision from European Commission Expected in Q1 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company’s Executive Vice President, Chief...
Themefolio
Profiler
Peergroup
© BusinessWire
17.11.2025
CYTK
LISTED
NASDAQ
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compa...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.11.2025
CYTK
LISTED
NASDAQ
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
News Preview
System of Care to Advance Care for the Most Commonly Inherited Heart Disease...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
15.11.2025
CYTK
LISTED
NASDAQ
Cytokinetics 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
CYTK
LISTED
NASDAQ
Deadline Soon: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 17, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, i...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
News Preview
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
CYTK
LISTED
NASDAQ
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Cytokinetics
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of mi...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), at the Hypertrophic Cardiomyopathy Medica...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2025 it granted stock options to purchase an aggregate of 109,120 shares of common stock and 73,535 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 83 employees,...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
News Preview
Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Recovery Compared to Metoprolol...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
CYTK
LISTED
NASDAQ
Deadline Alert: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.09.2025
CYTK
LISTED
NASDAQ
Rosen Law Firm Urges Cytokinetics, Inc. (NASDAQ: CYTK) Stockholders to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025. Cytokinetics describes itself as a “biopharmaceutical company focused on discovering, developing, and commercializing first-in-c...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
News Preview
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:00 AM Eastern Time....
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
CYTK
LISTED
NASDAQ
Deadline Approaching: Cytokinetics, Incorporated (CYTK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming November 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”).
IF Y...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
CYTK
LISTED
NASDAQ
CYTOKINETICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, Llc Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company’s s...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
CYTK
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
CYTK
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Comm...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
CYTK
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a le...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
News Preview
Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 in a private placement (the “offering”) to persons reasonably believed to be qualified instit...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to p...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
CYTK
LISTED
NASDAQ
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
News Preview
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
News Preview
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
News Preview
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
CYTK
LISTED
NASDAQ
Cytokinetics Names Jim Daly to Board of Directors
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of common stock and 70,879 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 46 employees, w...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.07.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, who...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.05.2025
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
News Preview
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions...
Themefolio
Profiler
Peergroup
© BusinessWire
09.05.2025
CYTK
LISTED
NASDAQ
Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONE...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW OFFICES OF HOWARD G....
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
CYTK
LISTED
NASDAQ
Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON CYTOKINETICS, INCORPORATED (CYTK), CLICK HERE TO INQUIRE ABOUT POTENTIAL...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Themefolio
Profiler
Peergroup
© BusinessWire
02.05.2025
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinen...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
News Preview
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic ca...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.01.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of 52,188 shares of common stock, 33,885 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,189 performanc...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
CYTK
LISTED
NASDAQ
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
News Preview
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Great...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2024
CYTK
LISTED
NASDAQ
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
News Preview
Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.11.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
News Preview
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.11.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil we...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
News Preview
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.09.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
News Preview
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hyper...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
News Preview
Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.09.2024
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
News Preview
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers with Aficamten...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2024
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common stock, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs) that, if earned, will be settled in shares...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
CYTK
LISTED
NASDAQ
Cytokinetics Announces Pricing of Public Offering of Common Stock
News Preview
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offe...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
